OXiGENE's CEO resigns

OXiGENE's CEO resigns

Oct 12, 2009 (Datamonitor via COMTEX) -- OXGN | Quote | Chart | News | PowerRating -- OXiGENE, a clinical-stage biopharmaceutical company, has reported that its CEO, John Kollins, has resigned from his position with the company and as a member of the board of directors in order to pursue other interests. 
Peter Langecker, executive vice president and chief development officer, will serve as interim CEO while the company conducts a search for a permanent replacement for Mr Kollins.

William Shiebler, chairman of board of directors of OXiGENE, said: "On behalf of the board of directors, I want to thank John Kollins for his dedicated service and contributions to OXiGENE. We wish him success in his new endeavors."

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.